Xvivo Perfusion AB (publ)

Stockholm Stock Exchange XVIVO.ST

Xvivo Perfusion AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2024

Xvivo Perfusion AB (publ) Net Cash Used For Investing Activities is NA for the year ending December 31, 2024. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.
  • Xvivo Perfusion AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2023 was USD -15.95 M, a 15.48% change year over year.
  • Xvivo Perfusion AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -18.87 M, a 8.68% change year over year.
  • Xvivo Perfusion AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -20.67 M, a 36.03% change year over year.
  • Xvivo Perfusion AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -32.30 M, a -262.11% change year over year.
Key data
Date Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure
Market news
Loading...
SV Wall Street
Stockholm Stock Exchange: XVIVO.ST

Xvivo Perfusion AB (publ)

CEO Mr. Christoffer Rosenblad
IPO Date Oct. 8, 2012
Location Sweden
Headquarters MAessans gata 10
Employees 161
Sector Healthcare
Industries
Description

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

Similar companies

BIOA-B.ST

BioArctic AB (publ)

USD 18.98

-4.07%

IVSO.ST

Invisio AB (publ)

USD 30.29

2.33%

VITR.ST

Vitrolife AB (publ)

USD 19.80

-1.20%

HTRO.ST

Hexatronic Group AB (publ)

USD 3.11

-4.78%

CEVI.ST

CellaVision AB (publ)

USD 19.20

-5.48%

StockViz Staff

February 5, 2025

Any question? Send us an email